{"version":"1.0","type":"link","title":"Efficacy and safety of a reduced starting dose of cabozantinib (20 mg) plus nivolumab for renal cell carcinoma in real-world practice.","author_name":"Sazuka T 외","author_url":"https://prs-insight.online/author/Sazuka%20T","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/169814","thumbnail_width":1200,"thumbnail_height":630}